Century Therapeutics, INC. (IPSC) — SEC Filings

Overview

Century Therapeutics, INC. (IPSC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 16, 2026: Century Therapeutics, Inc. filed an Annual Report to Security Holders (ARS) on April 16, 2026, for the period ending December 31, 2025. The company is based in Philadelphia, PA, and operates in the Biological Products sector. The filing includes a complete submission text file and a PDF document.

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 3 bullish, 4 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Century Therapeutics, INC. is neutral.

Filing Type Overview

Century Therapeutics, INC. (IPSC) has filed 1 ARS, 23 8-K, 3 DEF 14A, 6 10-Q, 2 10-K, 5 SC 13G, 6 SC 13G/A, 1 8-K/A, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (48)

• Century Therapeutics Files Annual Report — ARS · Apr 16, 2026 Risk: low
  Century Therapeutics, Inc. filed an Annual Report to Security Holders (ARS) on April 16, 2026, for the period ending December 31, 2025. The company is based in
• 8-K Filing — 8-K · Dec 29, 2025
• Century Therapeutics Files 8-K — 8-K · Dec 12, 2025 Risk: low
  Century Therapeutics, Inc. filed an 8-K on December 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• 8-K Filing — 8-K · Dec 9, 2025
• Century Therapeutics Proposes Reverse Stock Split to Avoid Nasdaq Delisting — DEF 14A · Dec 2, 2025 Risk: high
  Century Therapeutics, Inc. (IPSC) is seeking stockholder approval for a reverse stock split of its common stock, with a ratio between 1-for-5 and 1-for-30, at a
• Century Therapeutics Swings to 9-Month Profit on Collaboration Windfall — 10-Q · Nov 13, 2025 Risk: high
  Century Therapeutics, Inc. (IPSC) reported a net income of $9,591,000 for the nine months ended September 30, 2025, a significant improvement from a net loss of
• Century Therapeutics Faces Delisting Notice — 8-K · Aug 29, 2025 Risk: high
  Century Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of Aug
• Century Therapeutics (IPSC) Files 8-K — 8-K · Aug 14, 2025 Risk: low
  On August 13, 2025, Century Therapeutics, Inc. (IPSC) filed an 8-K report. The filing indicates the company's principal executive offices are located at 25 Nort
• Century Therapeutics Swings to Profit on Bristol-Myers Squibb Deal Termination — 10-Q · Aug 14, 2025 Risk: high
  Century Therapeutics, Inc. (IPSC) reported a net income of $44.019 million for the six months ended June 30, 2025, a significant turnaround from a net loss of $
• Century Therapeutics Reports Exit Costs & Officer Changes — 8-K · Jul 7, 2025 Risk: medium
  Century Therapeutics, Inc. filed an 8-K on July 7, 2025, reporting on cost-associated exit or disposal activities and changes in directors and officers. The fil
• Century Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 16, 2025 Risk: low
  Century Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details t
• Century Therapeutics Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Century Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Century Therapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  Century Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information including retained earnings, additional
• Century Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 22, 2025 Risk: low
  Century Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 22, 2025, for its annual meeting on June 12, 2025. The filing concerns the so
• 8-K Filing — 8-K · Mar 19, 2025
• Century Therapeutics Files 2024 10-K — 10-K · Mar 19, 2025 Risk: medium
  Century Therapeutics, Inc. filed its 2024 10-K on March 19, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company,
• Century Therapeutics Faces Delisting Concerns — 8-K · Feb 28, 2025 Risk: high
  Century Therapeutics, Inc. filed an 8-K on February 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with t
• Century Therapeutics Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Century Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosure
• Century Therapeutics Terminates Material Agreement — 8-K · Dec 13, 2024 Risk: medium
  On December 12, 2024, Century Therapeutics, Inc. reported the termination of a material definitive agreement. The filing does not specify the counterparty or th
• SC 13G Filing — SC 13G · Nov 27, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Century Therapeutics Files 8-K — 8-K · Nov 5, 2024 Risk: low
  On November 5, 2024, Century Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and other events, along wit
• Century Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 5, 2024 Risk: medium
  Century Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position, including assets and li
• SC 13G/A Filing — SC 13G/A · Oct 25, 2024
• Century Therapeutics Appoints New CMO, Director — 8-K · Sep 26, 2024 Risk: medium
  Century Therapeutics, Inc. announced on September 26, 2024, the appointment of Dr. Lishan Chen as Chief Medical Officer and the election of Dr. David R. Boulwar
• Century Therapeutics Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, Century Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, al
• Century Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Century Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Key financial fig
• Century Therapeutics Files 8-K — 8-K · Jul 8, 2024 Risk: low
  On July 8, 2024, Century Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Century Therapeutics Files Amended Financials — 8-K/A · Jun 26, 2024 Risk: low
  Century Therapeutics, Inc. filed an amendment (8-K/A) on June 26, 2024, to include audited financial statements for Clade as of December 31, 2023, and unaudited
• Century Therapeutics Reports on Shareholder Vote Matters — 8-K · Jun 24, 2024 Risk: low
  Century Therapeutics, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders as of June 20, 2024. The filing does not
• EQT AB to Acquire Century Therapeutics for $1.5B — 8-K · Jun 3, 2024 Risk: medium
  Century Therapeutics, Inc. announced on June 3, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of EQT AB. The transaction
• Century Therapeutics Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
  Century Therapeutics, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Century Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Century Therapeutics, Inc. (IPSC) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Century Therapeutics, Inc. filed a 10-Q report on May 9, 2024, fo
• Century Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk: low
  Century Therapeutics, Inc. (IPSC) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Century Therapeu
• SC 13G Filing — SC 13G · Apr 25, 2024
• SC 13G Filing — SC 13G · Apr 22, 2024
• SC 13G Filing — SC 13G · Apr 18, 2024
• Century Therapeutics Files 8-K — 8-K · Apr 11, 2024 Risk: low
  On April 11, 2024, Century Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material ev
• EQT AB to Acquire Century Therapeutics for $1.5B — 8-K · Apr 9, 2024 Risk: medium
  Century Therapeutics, Inc. announced on April 8, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of EQT AB. The transaction
• Casdin Capital Ups Stake in Century Therapeutics — SC 13D/A · Apr 8, 2024 Risk: medium
  Casdin Capital, LLC, through its affiliate Casdin Capital, L.P., has amended its Schedule 13D filing regarding Century Therapeutics, Inc. As of February 29, 202
• Century Therapeutics Files 8-K on Financials — 8-K · Mar 14, 2024 Risk: low
  Century Therapeutics, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation F
• Century Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024 Risk: medium
  Century Therapeutics, Inc. (IPSC) filed a Annual Report (10-K) with the SEC on March 14, 2024. Century Therapeutics, Inc. filed its 2023 Form 10-K on March 14,
• SC 13G Filing — SC 13G · Mar 4, 2024
• FMR LLC Discloses 6.037% Stake in Century Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership stake in Century Therapeutics, Inc. This SC 13G/A filing, an ame
• Versant Ventures Holds 11.45M CNTX Shares as of Dec 31, 2023 — SC 13G/A · Feb 8, 2024 Risk: low
  Versant Venture Capital VI, L.P. has updated its ownership stake in Century Therapeutics, Inc. (NASDAQ: "CNTX"), reporting beneficial ownership of 11,452,014 sh
• Century Therapeutics Files 8-K on Officer/Director Changes, Comp — 8-K · Jan 19, 2024
  Century Therapeutics, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 15, 2024. This filing indicates a change in leadership

Risk Profile

Risk Assessment: Of IPSC's 35 recent filings, 5 were flagged as high-risk, 10 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Century Therapeutics, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $109,164,000
• Net Income: $9,591,000
• EPS: N/A
• Debt-to-Equity: 0.39
• Cash Position: $132,748,000
• Operating Margin: 3.2%
• Total Assets: $244,717,000
• Total Debt: $68,369,000

Key Executives

• Brent Pfeiffenberger, Pharm.D.
• Douglas Carr
• Lishan Chen
• David R. Boulware
• Eli Casdin
• Abigail P. Johnson

Industry Context

The biotechnology sector, particularly companies focused on early-stage therapeutics, often faces significant capital requirements and regulatory hurdles. Companies like Century Therapeutics are highly dependent on achieving clinical milestones and securing funding to advance their pipelines. The competitive landscape is intense, with many companies vying for investor attention and limited capital, making adherence to exchange listing requirements critical for maintaining visibility and access to public markets.

Top Tags

biotech (7) · sec-filing (4) · 8-k (4) · Biotechnology (4) · financial-condition (4) · 10-Q (4) · financials (4) · corporate-governance (3) · amendment (3) · institutional-ownership (3)

Key Numbers

• Nasdaq minimum bid price requirement: $1.00 — Century Therapeutics failed to meet this requirement, leading to the proposed reverse stock split.
• Reverse stock split ratio range: 1-for-5 and 1-for-30 — The Board has discretion to choose any whole number ratio within this range.
• Date of Nasdaq deficiency letter: February 26, 2025 — Century Therapeutics was notified of non-compliance with the minimum bid price rule.
• Initial Compliance Date: August 26, 2025 — Century Therapeutics did not regain compliance by this date.
• Extended Compliance Date: February 23, 2026 — New deadline for Century Therapeutics to regain Nasdaq compliance.
• Shares of Common Stock outstanding: 87,313,356 — As of November 15, 2025, before any reverse stock split.
• Beneficial ownership by Bayer World Investments B.V.: 14.52% — Largest beneficial owner of Century Therapeutics common stock.
• Beneficial ownership by Versant Entities: 13.93% — Second largest beneficial owner of Century Therapeutics common stock.
• Special Meeting time: 9:00 a.m., Eastern Time — The virtual Special Meeting will be held at this time on January 22, 2026.
• Date Board approved reverse stock split: November 18, 2025 — The Board unanimously approved the proposal to seek stockholder approval.
• Net income for nine months ended Sept 30, 2025: $9.591M — Driven by $109.164M collaboration revenue from Bristol-Myers Squibb termination
• Net loss for three months ended Sept 30, 2025: ($34.422M) — Increased from ($31.226M) in the prior year quarter
• Collaboration revenue for nine months ended Sept 30, 2025: $109.164M — Recognized upon termination of agreement with Bristol-Myers Squibb
• Net cash used in operating activities for nine months ended Sept 30, 2025: $87.799M — Indicates significant cash burn
• Cash and cash equivalents and investments as of Sept 30, 2025: $132.748M — Decreased from $194.051M at Dec 31, 2024

Forward-Looking Statements

• {"claim":"FMR LLC will maintain a significant, albeit potentially fluctuating, stake in Century Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
• {"claim":"Versant Venture Capital VI, L.P. will maintain a significant stake in Century Therapeutics, Inc.","entity":"Versant Venture Capital VI, L.P.","targetDate":"December 31, 2024","confidence":"medium"}

Related Companies

BMY · CTSO · CTRS

Frequently Asked Questions